Usefulness of factor II and factor X as therapeutic markers in patients under chronic warfarin therapy

Biomedicine and Pharmacotherapy

Volumn 64, Issue 2, 2010, Pages 130-132

  Costa, I M ^a   Serralheiro, A I ^b   Rodrigues, M ^b   Alves, G ^c   Falcao A C ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

Anticoagulant response markers; Clotting factors; Warfarin therapy

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10; PROTHROMBIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG MONITORING; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BIOMARKERS, PHARMACOLOGICAL; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; FACTOR X; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN; WARFARIN;

EID: 77349094508     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.09.020     Document Type: Article

References (18)

1. Buck M.L. Anticoagulation with warfarin in infants and children. Ann Pharmacother 1996, 30:1316-1322.
2. Holford N.H.G. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986, 11:483-504.
3. Murray B., Coleman R., McWaters D., Ludden T., Mungall D. Pharmacodynamics of warfarin at steady-state. Ther Drug Monit 1987, 9:1-5.
4. Wittkowsky A.K. Generic warfarin: implications for patient care. Pharmacotherapy 1997, 17:640-643.
5. Wiedermann C.J., Stockner I. Warfarin-induced bleeding complications: clinical presentation and therapeutic options. Thromb Res 2008, 122(Suppl. 2):S13-S18.
6. Merli G.J., Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?. J Thromb Thrombolysis 2009, 27:293-299.
7. Hoppensteadt D.A., Khan S., Fareed J. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombotic drugs. Clin Chem 1997, 43:1786-1788.
8. Lind S.E., Callas P.W., Golden E.A., Joyner K.A., Ortel T.L. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997, 8:48-53.
9. Chan E., Aarons L., Serlin M., Breckenridge A., Rowland M. Interrelationship among individual vitamin K-dependent clotting factors at different levels of anticoagulation. Br J Clin Pharmacol 1987, 24:621-625.
10. Porter RS, Sawyer WT. Warfarin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 3rd ed. Vancouver: Applied Therapeutics Inc. 1992. p. 31.1-31.46.
11. Howard P.A. Monitoring warfarin therapy with the international normalized ratio. Ann Pharmacother 1994, 28:242-244.
12. Iorio A., Agnelli G. Pharmacokinetic optimisation of the treatment of deep vein thrombosis. Clin Pharmacokinet 1997, 32:145-172.
13. Aiach M., Fiessinger J.N., Capron L., Nussas C., Housset E., Leclerc M. Kinetic study of factor X during oral anticoagulation with acenocoumarol, potential value for the initiation of treatment. Thromb Haemost 1982, 47:69-71.
14. Paul B., Oxley A., Brigham K., Cox T., Hamilton P.J. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987, 40:94-98.
15. Costa I.M., Soares P.J., Afonso M., Ratado P., Lanao J.M., Falcão A.C. Therapeutic monitoring of warfarin: the appropriate response marker. J Pharm Pharmacol 2000, 52:1405-1410.
16. Carr M.E. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 1988, 59:535-539.
17. Bänninger H., Lämmle B., Furlan M. Binding of α-thrombin to fibrin depends on the quality of the fibrin network. Biochem. J 1994, 298:157-163.
18. Sarode R., Rawal A., Lee R., Shen Y.M., Frenkel E.P. Poor correlation of subtherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Heamatol 2005, 132:604-607.